These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 24903374)
21. Biomaterials for the Delivery of Growth Factors and Other Therapeutic Agents in Tissue Engineering Approaches to Bone Regeneration. Kowalczewski CJ; Saul JM Front Pharmacol; 2018; 9():513. PubMed ID: 29896102 [TBL] [Abstract][Full Text] [Related]
22. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Fu R; Selph S; McDonagh M; Peterson K; Tiwari A; Chou R; Helfand M Ann Intern Med; 2013 Jun; 158(12):890-902. PubMed ID: 23778906 [TBL] [Abstract][Full Text] [Related]
23. A Comparative Study of Defibrillator Leads at a Large-Volume Implanting Hospital: Results From the Pacemaker and Implantable Defibrillator Leads Survival Study ("PAIDLESS"). Cohen TJ; Asheld WJ; Germano J; Islam S; Patel D J Invasive Cardiol; 2015 Jun; 27(6):292-300. PubMed ID: 26028656 [TBL] [Abstract][Full Text] [Related]
24. Regulation of yodA encoding a novel cadmium-induced protein in Escherichia coli. Puškarova A; Ferianc P; Kormanec J; Homerova D; Farewell A; Nyström T Microbiology (Reading); 2002 Dec; 148(Pt 12):3801-3811. PubMed ID: 12480884 [TBL] [Abstract][Full Text] [Related]
25. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings? Guzman JZ; Merrill RK; Kim JS; Overley SC; Dowdell JE; Somani S; Hecht AC; Cho SK; Qureshi SA Spine J; 2017 Sep; 17(9):1247-1254. PubMed ID: 28456674 [TBL] [Abstract][Full Text] [Related]
26. How drugs are developed and approved by the FDA: current process and future directions. Ciociola AA; Cohen LB; Kulkarni P; Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999 [TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of the Impact of Patient Characteristics on Estimates of Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Lumbar Spinal Fusion. Laurie AL; Chen Y; Chou R; Fu R Spine (Phila Pa 1976); 2016 Sep; 41(18):E1115-E1123. PubMed ID: 27031772 [TBL] [Abstract][Full Text] [Related]
28. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502 [TBL] [Abstract][Full Text] [Related]
29. The debate on FDA reform: a view from the U.S. Senate. Food and Drug Administration. Baker R BETA; 1995 Sep; ():41-4. PubMed ID: 11362892 [TBL] [Abstract][Full Text] [Related]
30. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Carragee EJ; Hurwitz EL; Weiner BK Spine J; 2011 Jun; 11(6):471-91. PubMed ID: 21729796 [TBL] [Abstract][Full Text] [Related]
31. Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database. Woo EJ Spine J; 2012 Oct; 12(10):894-9. PubMed ID: 23098616 [TBL] [Abstract][Full Text] [Related]
32. Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review. Faundez A; Tournier C; Garcia M; Aunoble S; Le Huec JC Int Orthop; 2016 Jun; 40(6):1309-19. PubMed ID: 26961193 [TBL] [Abstract][Full Text] [Related]
33. The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion. Glassman SD; Carreon LY; Campbell MJ; Johnson JR; Puno RM; Djurasovic M; Dimar JR Spine J; 2008; 8(3):443-8. PubMed ID: 17526436 [TBL] [Abstract][Full Text] [Related]
34. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316 [TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of bioabsorbable cervical spacers and low-dose rhBMP-2 in multi-level ACDF. Khajavi K; Shen A Int J Spine Surg; 2014; 8():. PubMed ID: 25694938 [TBL] [Abstract][Full Text] [Related]
36. Recombinant human bone morphogenetic protein-2 versus iliac crest bone graft in anterior cervical discectomy and fusion: Dysphagia and dysphonia rates in the early postoperative period with review of the literature. Riederman BD; Butler BA; Lawton CD; Rosenthal BD; Balderama ES; Bernstein AJ J Clin Neurosci; 2017 Oct; 44():180-183. PubMed ID: 28716569 [TBL] [Abstract][Full Text] [Related]
37. A historic moment for open science: the Yale University Open Data Access project and medtronic. Krumholz HM; Ross JS; Gross CP; Emanuel EJ; Hodshon B; Ritchie JD; Low JB; Lehman R Ann Intern Med; 2013 Jun; 158(12):910-1. PubMed ID: 23778908 [No Abstract] [Full Text] [Related]
38. Using Medtronic's MAST Quadrant, Radiance, and Radiance X Illumination Systems with high-power light sources increases burn risk. Health Devices; 2010 Nov; 39(11):420-1. PubMed ID: 21306044 [TBL] [Abstract][Full Text] [Related]
39. YodA from Escherichia coli is a metal-binding, lipocalin-like protein. David G; Blondeau K; Schiltz M; Penel S; Lewit-Bentley A J Biol Chem; 2003 Oct; 278(44):43728-35. PubMed ID: 12909634 [TBL] [Abstract][Full Text] [Related]
40. A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research. Carragee EJ; Baker RM; Benzel EC; Bigos SJ; Cheng I; Corbin TP; Deyo RA; Hurwitz EL; Jarvik JG; Kang JD; Lurie JD; Mroz TE; Oner FC; Peul WC; Rainville J; Ratliff JK; Rihn JA; Rothman DJ; Schoene ML; Spengler DM; Weiner BK Spine J; 2012 Oct; 12(10):877-80. PubMed ID: 23199819 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]